Back HIV Prevention Pre-exposure (PrEP)

Pre-exposure Prophylaxis (PrEP)

IAS 2017: Long-Acting Cabotegravir Shows Promise For HIV Prevention

A long-acting injectable formulation of cabotegravir given every 8 weeks produces high enough drugs levels in both men and women to offer protection against HIV, according to results from the HPTN 077 study presented this week at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris. But another injectable prevention candidate, long-acting rilpivirine, has been abandoned.

alt

Read more:

IAS 2017: PrEP Still Protected People Who Had Less Sex in Ipergay Study

A sub-study of the French Ipergay trial of "on-demand" pre-exposure prophylaxis (PrEP) has found that PrEP was just as effective for participants who had sex less often than average, and so took PrEP less often, as long as they did take it when it was needed. The analysis was presented by trial statistician Guillemette Antoni at the 9th International AIDS Society Conference (IAS 2017) conference this week in Paris.

alt

Read more:

HIV PrEP Is Approved in Scotland

The Scottish Medicines Consortium (SMC) announced this week that it had accepted tenofovir disoproxil fumarate/emtricitabine (Truvada) for use within the Scottish National Health Service as pre-exposure prophylaxis (PrEP) to prevent HIV infection.

alt

Read more:

PAS 2017: Many Doctors Wary of Providing PrEP for Young Patients

Only about a third of family practice and pediatric providers said they would be likely to prescribe HIV pre-exposure prophylaxis (PrEP) to adolescent patients, underlining the need to educate providers outside the HIV and sexually transmitted disease fields, according to a report at the 2017 Pediatric Academic Societies Meeting last week in San Francisco.

alt

Read more:

BHIVA 2017: Large Fall in London HIV Diagnoses Is Due to Combination Prevention, Not Just PrEP

The number of new HIV diagnoses among gay men attending 5 key London clinics fell substantially during 2015 and 2016, Valerie Delpech of Public Health England reported at the British HIV Association (BHIVA) conference last week in Liverpool.

alt

Read more: